GNPX:NASDAQ, Genprex, Inc.
GNPX stock overview
Genprex, Inc. (GNPX:NASDAQ) closed at $1.90 on November 16, 2026,
down 8.65% on the day.
The stock trades 98.1% below its 52-week high of $98.76
and 11.1% above its 52-week low of $1.71.
Over the past year, it lost 97.9%.
Genprex, Inc. is part of the Health Care sector (Major Pharmaceuticals).
Key figures
- Price
- $1.90
- Day change
- -8.65%
- Volume
- 116,062
- Average volume
- 241,565
- Market cap
- 1M+
- 52-week range
- $1.71 – $98.76
- 50-day average
- $2.65
- 200-day average
- $17.55
Price action over the past year
In 252 trading sessions since November 14, 2025, GNPX closed higher on 95 days (38%).
Its best day was February 23, 2026 (+27.53%) and its worst was July 16, 2026 (-25.94%).
The stock moved 10% or more in a single session 30 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
GNPX news
-
Nov 11, 2026:
Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium
-
Nov 5, 2026:
Genprex Presents Data Showing Reqorsa Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress
-
Nov 5, 2026:
Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress
-
Nov 4, 2026:
Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa Gene Therapy in Lung Cancer
-
Nov 4, 2026:
Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer
-
Oct 28, 2026:
Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting
-
Oct 21, 2026:
Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA, in Maintaining Cellular Function During Brain Aging
-
Oct 21, 2026:
Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging
About Genprex, Inc.
Genprex Inc is a clinical stage gene therapy company. It develops therapies that carry cancer-fighting genes. Its initial product candidate is Oncoprex.
Similar stocks
Find more stocks like GNPX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.